Cargando…
Drug Repurposing at the Interface of Melanoma Immunotherapy and Autoimmune Disease
Cancer cells have a remarkable ability to evade recognition and destruction by the immune system. At the same time, cancer has been associated with chronic inflammation, while certain autoimmune diseases predispose to the development of neoplasia. Although cancer immunotherapy has revolutionized ant...
Autores principales: | Spitschak, Alf, Gupta, Shailendra, Singh, Krishna P., Logotheti, Stella, Pützer, Brigitte M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865219/ https://www.ncbi.nlm.nih.gov/pubmed/36678712 http://dx.doi.org/10.3390/pharmaceutics15010083 |
Ejemplares similares
-
STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases
por: Logotheti, Stella, et al.
Publicado: (2019) -
Logic-based modeling and drug repurposing for the prediction of novel therapeutic targets and combination regimens against E2F1-driven melanoma progression
por: Singh, Nivedita, et al.
Publicado: (2023) -
Mechanisms of Functional Pleiotropy of p73 in Cancer and Beyond
por: Logotheti, Stella, et al.
Publicado: (2021) -
LncRNA-SLC16A1-AS1 induces metabolic reprogramming during Bladder Cancer progression as target and co-activator of E2F1
por: Logotheti, Stella, et al.
Publicado: (2020) -
Rewiring E2F1 with classical NHEJ via APLF suppression promotes bladder cancer invasiveness
por: Richter, Christin, et al.
Publicado: (2019)